Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2011

Open Access 01-12-2011 | Research article

Decreased CD8+T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes

Authors: Michael P Pender, Peter A Csurhes, Casey MM Pfluger, Scott R Burrows

Published in: BMC Neurology | Issue 1/2011

Login to get access

Abstract

Background

Patients with multiple sclerosis (MS) have a decreased frequency of CD8+ T cells reactive to their own Epstein-Barr virus (EBV) infected B cells. We have proposed that this might predispose to the development of MS by allowing EBV-infected autoreactive B cells to accumulate in the central nervous system. The decreased CD8+ T cell response to EBV results from a general CD8+ T cell deficiency and also a decreased proportion of EBV-specific T cells within the total CD8+ T cell population. Because decreased HLA class I expression on monocytes and B cells has been reported in MS and could influence the generation and effector function of EBV-specific CD8+ T cells, the present study was undertaken to measure the expression of HLA molecules on B cells and monocytes in patients with MS.

Methods

We used flow cytometry to determine the proportions of T cells, natural killer cells, B cells and monocytes in peripheral blood mononuclear cells (PBMC) and to quantify the expression of HLA molecules on T cells, B cells and monocytes of 59 healthy subjects and 62 patients with MS who had not received corticosteroids or immunomodulatory therapy in the previous 3 months.

Results

The levels of HLA class I and class II molecules expressed on T cells, B cells and monocytes were normal in patients with MS, with the exception of two patients with secondary progressive MS with very low class II expression on B cells. In confirmation of previous studies we also found that the percentage of CD8+ T cells was significantly decreased whereas the percentage of CD4+ T cells and the CD4:CD8 ratio were significantly increased in patients with MS compared to healthy subjects.

Conclusions

The decreased CD8+ T cell response to EBV-infected B cells in MS patients is not due to decreased HLA class I expression on monocytes or B cells. In a small proportion of patients decreased HLA class II expression on B cells might impair the CD8+ T cell response to EBV by reducing CD4+ T cell help.
Literature
1.
Ascherio A, Munger KL: Epstein-Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol. 2010, 5: 271-277. 10.1007/s11481-010-9201-3.CrossRefPubMed
2.
Santiago O, Gutierrez J, Sorlozano A, de Dios Luna J, Villegas E, Fernandez O: Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production. Eur J Clin Microbiol Infect Dis. 2010, 29: 857-866. 10.1007/s10096-010-0940-0.CrossRefPubMed
3.
Pender MP: The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist. 2011, 17: 351-367. 10.1177/1073858410381531.CrossRefPubMedPubMedCentral
4.
Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, Hjorth P, Sondergaard L, Svejgaard A, Wucherpfennig K, Stuart DI, Bell JI, Jones EY, Fugger L: A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol. 2002, 3: 940-943. 10.1038/ni835.CrossRefPubMed
5.
Van Noort JM, Bajramovic JJ, Plomp AC, van Stipdonk MJB: Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol. 2000, 105: 46-57. 10.1016/S0165-5728(00)00181-8.CrossRefPubMed
6.
Pender MP: Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 2003, 24: 584-588. 10.1016/j.it.2003.09.005.CrossRefPubMed
7.
Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F: Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007, 204: 2899-2912. 10.1084/jem.20071030.CrossRefPubMedPubMedCentral
8.
Krone B, Grange JM: Multiple sclerosis: are protective immune mechanisms compromised by a complex infectious background?. Autoimmune Dis. 2010, 2011: 708750-PubMedPubMedCentral
9.
Pender MP: Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev. 2009, 8: 563-568. 10.1016/j.autrev.2009.01.017.CrossRefPubMed
10.
Hislop AD, Taylor GS, Sauce D, Rickinson AB: Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007, 25: 587-617. 10.1146/annurev.immunol.25.022106.141553.CrossRefPubMed
11.
Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, Perkal H, Caballero E, Münz C, Montalban X, Comabella M: Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol. 2010, 67: 159-169. 10.1002/ana.21886.CrossRefPubMedPubMedCentral
12.
Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A, Kleeberg J, Le Goff G, Pantaleo G, Du Pasquier RA: Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain. 2008, 131: 1712-1721. 10.1093/brain/awn108.CrossRefPubMed
13.
Gronen F, Ruprecht K, Weissbrich B, Klinker E, Kroner A, Hofstetter HH, Rieckmann P: Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls. J Neuroimmunol. 2006, 180: 185-192. 10.1016/j.jneuroim.2006.08.008.CrossRefPubMed
14.
Höllsberg P, Hansen HJ, Haahr S: Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol. 2003, 132: 137-143. 10.1046/j.1365-2249.2003.02114.x.CrossRefPubMedPubMedCentral
15.
Pender MP, Csurhes PA, Lenarczyk A, Pfluger CMM, Burrows SR: Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009, 80: 498-505. 10.1136/jnnp.2008.161018.CrossRefPubMed
16.
Pender MP, Csurhes PA, Pfluger CMM, Burrows SR: CD8 T cell deficiency impairs control of Epstein-Barr virus and worsens with age in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011
17.
Cepok S, Zhou D, Srivastava R, Nessler S, Stei S, Büssow K, Sommer N, Hemmer B: Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest. 2005, 115: 1352-1360.CrossRefPubMedPubMedCentral
18.
Craig JC, Hawkins SA, Swallow MW, Lyttle JA, Patterson VH, Merrett JD, Haire M: Subsets of T lymphocytes in relation to T lymphocyte function in multiple sclerosis. Clin Exp Immunol. 1985, 61: 548-555.PubMedPubMedCentral
19.
Lindsey JW, Hatfield LM: Epstein-Barr virus and multiple sclerosis: cellular immune response and cross-reactivity. J Neuroimmunol. 2010, 229: 238-242. 10.1016/j.jneuroim.2010.08.009.CrossRefPubMed
20.
Li F, Linan MJ, Stein MC, Faustman DL: Reduced expression of peptide-loaded HLA class I molecules on multiple sclerosis lymphocytes. Ann Neurol. 1995, 38: 147-154. 10.1002/ana.410380205.CrossRefPubMed
21.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung H-P, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2005 Revisions to the "McDonald Criteria". Ann Neurol. 2005, 58: 840-846. 10.1002/ana.20703.CrossRefPubMed
22.
Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983, 33: 1444-1452.CrossRefPubMed
23.
Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA: Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005, 64: 1144-1151. 10.1212/01.WNL.0000156155.19270.F8.CrossRefPubMed
24.
Kouwenhoven M, Teleshova N, Özenci V, Press R, Link H: Monocytes in multiple sclerosis: phenotype and cytokine profile. J Neuroimmunol. 2001, 112: 197-205. 10.1016/S0165-5728(00)00396-9.CrossRefPubMed
25.
Gudgeon NH, Taylor GS, Long HM, Haigh TA, Rickinson AB: Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity. J Virol. 2005, 79: 5477-5488. 10.1128/JVI.79.9.5477-5488.2005.CrossRefPubMedPubMedCentral
26.
Reinherz EL, Weiner HL, Hauser SL, Cohen JA, Distaso JA, Schlossman SF: Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med. 1980, 303: 125-129. 10.1056/NEJM198007173030303.CrossRefPubMed
27.
Bach M-A, Phan-Dinh-Tuy F, Tournier E, Chatenoud L, Bach J-F, Martin C, Degos J-D: Deficit of suppressor T cells in active multiple sclerosis. Lancet. 1980, 316: 1221-1223. 10.1016/S0140-6736(80)92480-0.CrossRef
28.
29.
Antel JP, Peeples DM, Reder AT, Arnason BGW: Analysis of T regulator cell surface markers and functional properties in multiple sclerosis. J Neuroimmunol. 1984, 6: 93-103. 10.1016/0165-5728(84)90030-4.CrossRefPubMed
30.
Thompson AJ, Brazil J, Whelan CA, Martin EA, Hutchinson M, Feighery C: Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse?. J Neurol Neurosurg Psychiatry. 1986, 49: 905-912. 10.1136/jnnp.49.8.905.CrossRefPubMedPubMedCentral
31.
Trotter JL, Clifford DB, McInnis JE, Griffeth RC, Bruns KA, Perlmutter MS, Anderson CB, Collins KG, Banks G, Hicks BC: Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol. 1989, 25: 172-178. 10.1002/ana.410250211.CrossRefPubMed
32.
Kreuzfelder E, Shen G, Bittorf M, Scheiermann N, Thraenhart O, Seidel D, Grosse-Wilde H: Enumeration of T, B and natural killer peripheral blood cells of patients with multiple sclerosis and controls. Eur Neurol. 1992, 32: 190-194. 10.1159/000116820.CrossRefPubMed
33.
Michałowska-Wender G, Wender M: Mononuclear subsets in the peripheral blood of multiple sclerosis patients in relation to results of brain gadolinium-enhancing imaging. Folia Neuropathol. 2006, 44: 67-71.PubMed
34.
Amadori A, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli GA, Clementi M, Chieco-Bianchi L: Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med. 1995, 1: 1279-1283. 10.1038/nm1295-1279.CrossRefPubMed
35.
Ferreira MAR, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F, International HIV Controllers Study, Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PI, Frazer IH, Montgomery GW, Martin NG: Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet. 2010, 86: 88-92. 10.1016/j.ajhg.2009.12.008.CrossRefPubMedPubMedCentral
36.
Jabs DA, Arnett FC, Bias WB, Beale MG: Familial abnormalities of lymphocyte function in a large Sjögren's syndrome kindred. J Rheumatol. 1986, 13: 320-326.PubMed
37.
Johnston C, Alviggi L, Millward BA, Leslie RDG, Pyke DA, Vergani D: Alterations in T-lymphocyte subpopulations in type 1 diabetes. Exploration of genetic influence in identical twins. Diabetes. 1988, 37: 1484-1488. 10.2337/diabetes.37.11.1484.CrossRefPubMed
38.
Johansen M, Elling P, Elling H, Olsson A: A genetic approach to the aetiology of giant cell arteritis: depletion of the CD8+ T-lymphocyte subset in relatives of patients with polymyalgia rheumatica and arteritis temporalis. Clin Exp Rheumatol. 1995, 13: 745-748.PubMed
Metadata
Title
Decreased CD8+T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes
Authors
Michael P Pender
Peter A Csurhes
Casey MM Pfluger
Scott R Burrows
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2011
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-11-95

Other articles of this Issue 1/2011

BMC Neurology 1/2011 Go to the issue

Research article

Health-related quality of life in adults with epilepsy: the effect of age, age at onset and duration of epilepsy in a multicentre Italian study

Debate

Pros and cons of a prion-like pathogenesis in Parkinson's disease

Research article

Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid

Erratum

Erratum to:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study

Research article

Corticosteroid and antiviral therapy for Bell's palsy: A network meta-analysis

Study protocol

Research into the (Cost-) effectiveness of the ketogenic diet among children and adolescents with intractable epilepsy: design of a randomized controlled trial